Navigation Links
Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model
Date:4/8/2008

Research To Be Presented at American Association of Immunologists Meeting

SOUTH SAN FRANCISCO, Calif., April 8, 2008 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its oral Syk kinase inhibitor, R788, may be a useful treatment for type 1 diabetes mellitus, according to research being presented at the American Association of Immunologists meeting in San Diego, California on April 8, 2008. Using Rigel's R788, researchers from the Department of Medicine at Columbia University Medical Center have shown that blocking Syk kinase in a well-established murine model of type 1 diabetes, delayed the onset of diabetes and prolonged survival. A reduction in the production of insulin-specific autoantibodies, an early event in type 1 diabetes pathogenesis, was also observed.

"Inhibition of the Syk kinase has the potential to reduce both autoantibody production and disarm its pathogenic consequences," said Raphael Clynes M.D., Ph.D., assistant professor in Medicine and Microbiology at Columbia University's College of Physician's and Surgeons. "In diabetes, autoantibodies against islet cells appear before the actual onset of disease providing the opportunity to intervene and disable these early events prior to immune destruction of the insulin-producing cells in the pancreas. The protection we see in these mouse models suggests that pharmacologic blockade of Syk with R788 may provide a good therapeutic strategy to treat and potentially prevent the onset or advancement of type 1 diabetes," he added.

Type 1 Diabetes and R788

According to the Juvenile Diabetes Research Foundation, type 1 diabetes, also called juvenile diabetes or insulin-dependent diabetes, occurs when the body's immune syst
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. New Study Shows Proprietary Canola Extract, Dermytol(TM), Produces Pronounced Decrease in Malignant Melanoma Tumor Volume
2. New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion
3. TAXUS(R) Express(TM) Stent Shows Similarly Low Re-intervention Rates in Diabetic Patients Compared to Non-Diabetics in ARRIVE 1 and 2 registries
4. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
5. Study Data Shows VNUS ClosureFAST(TM) Catheter More than 96% Effective
6. Study Shows: New Blood Test Proven Six Times More Effective For Tuberculosis Control
7. Pixantrone Shows Activity in a Preclinical Study of Experimental Autoimmune Myasthenia Gravis (EAMG)
8. Novel Small Molecule Therapy Shows Benefit for Anemic Patients Via Hydration of Red Blood Cells
9. JAK2 Inhibitor Shows Potent Activity in Cells From MPD Patients
10. Newly Approved HIV Drug Shows Great Promise
11. Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 2014 PositiveID Corp. (OTCQB: PSID), based in ... an emerging player in the bio-threat detection market, ... and rapid medical testing. The Company,s proprietary airborne ... Networked Detector), was developed under contract with the ... Technology directorate, and $30 million of contract funding. ...
(Date:7/23/2014)... Pa. , July 23, 2014 /PRNewswire/ ... today announced successful results from its randomized, ... in women with biopsy-proven cervical intraepithelial neoplasia ... types 16 or 18. Treatment with VGX-3100, ... of CIN2/3 to CIN1 or no disease, ...
(Date:7/23/2014)... -- Nearly 8,000 attendees will converge in Washington ... Conference (RBC), taking place July 23-26 at the Gaylord ... pharmacists to "Lead Change" in the pharmacy profession, in ... their future. "RBC is the perfect opportunity ... and learn new ways they can lead change in ...
Breaking Medicine Technology:PositiveID Analyst Inspection: Emerging Contender in BioThreat Detection - First Ever Revenue Guidance and Backlog Position Company for Increased Visibility and Traction - by SmallCapTraders.com 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 2Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 3Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 4Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 2Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 3Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 4Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 5Cardinal Health Encourages Independent Pharmacists to Lead Change at 24th Annual Retail Business Conference 6
...  Responding to a need for better post-market surveillance of orthopedic ... Consortium of Orthopaedic Registries in October 2010. As ... Journal of Bone and Joint Surgery , ... for improving the safety of orthopedic devices using outcomes registries ...
... Dec. 21, 2011 Senate Democratic Leader John L. ... and CEO of Walgreens Inc., expressing his dismay about ... drug coverage more affordable for many of the low-income ... Walgreens has administered the program through Express Scripts, ...
Cached Medicine Technology:Unprecedented International Effort Seeks to Improve Safety of Orthopedic Devices 2Unprecedented International Effort Seeks to Improve Safety of Orthopedic Devices 3Unprecedented International Effort Seeks to Improve Safety of Orthopedic Devices 4
(Date:7/23/2014)... 2014 The next episode of “Extreme ... Wis. who was physically fit through childhood and adolescence. ... made the heart-wrenching decision to give her son up ... past 18 years, and she punished herself by overeating, ... a unique, non-competitive approach to weight loss transformations, “Extreme ...
(Date:7/23/2014)... 23, 2014 Home Care Assistance ... for seniors, is proud to announce the next installment ... in a wide range of health and wellness-related fields. ... and award-winning author Nancy Kriseman, and will cover the ... prevent burnout by becoming more self-aware. In particular, Nancy ...
(Date:7/23/2014)... or itchy skin lesions could be a warning sign ... multiple lesions that are suspicious looking, and those that ... non-melanoma skin cancers," study author Dr. Gil Yosipovitch, chairman ... in a Temple University Health System news release. ... who were confirmed to have skin cancer lesions between ...
(Date:7/23/2014)... body of research suggesting a safe and effective ... breast cancer, with fewer detrimental side effects and ... The study will be published in final format ... and Endocrinology . , Breast cancer is the ... United States. Approximately 70% of breast cancers are ...
(Date:7/23/2014)... The National Institute of Biomedical Imaging and Bioengineering ... Symposium on July 30, 2014 on the NIH campus. ... investigators covering a wide breadth of NIBIB-funded research. ... Cohen, Harvard, Engineering Microbial Rhodopsins as Optical Voltage Sensor, ... Fluorescently Labeled Probes for Nerve Imaging ...
Breaking Medicine News(10 mins):Health News:“Extreme Weight Loss”: Cassie’s journey begins at the University of Colorado Anschutz Health and Wellness Center 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 2Health News:Home Care Assistance Calgary to Host Public Webinar on the Topic of Caregiver Mindfulness 3Health News:Painful, Itchy Patches Could Be Sign of Skin Cancer 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5
... Dec. 15 Today, the U.S. Food,and Drug Administration ... along with diet to help lower triglycerides,and LDL cholesterol, ... TRILIPIX is the first and only fibrate to ... In certain patients, treatment guidelines,recommend the combination of a ...
... Matthew L. Myers President, Campaign for Tobacco-Free Kids , ... U.S. Supreme Court today handed down a major victory for ... state consumer protection laws to sue Philip Morris and other ... Today,s ruling poses a significant legal threat to the ...
... Controlling Costs, Improving Quality as Health Care Reform Debate Centers on ... Dec. 15 House Ways and Means Health Subcommittee Chairman ... counsel to Sen. Max Baucus, will join health care expert and ... Future co-director Roger Hickey on a conference call with ...
... Dec. 15 Following is a statement from Michael ... in regards to its financial exposure with Madoff Securities: ... Health System,s financial exposure with Madoff Securities is limited to ... who stipulated that the funds be invested with Madoff. The ...
... Dec. 15 The American Red Cross sheltered hundreds of people ... Northeast. Working with local partners, Red Cross chapters opened shelters in ... , "Unfortunately, ice storms are par for ... is always ready to give people a safe and warm place ...
... Lab study showed it had effect on 60% Of malignant ... produced by the oncogene MYC can stop the spread of ... that has the potential to help cause cancer. , In ... overly active. This causes the ovarian cells to produce excessive ...
Cached Medicine News:Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 2Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 3Health News:Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 4Health News:U.S. Supreme Court Ruling Allowing Light Cigarette Lawsuits Is Victory for Consumers and Health 2Health News:U.S. Supreme Court Ruling Allowing Light Cigarette Lawsuits Is Victory for Consumers and Health 3Health News:North Shore-LIJ Health System Exposure With Madoff Securities Limited to $5.7M 2Health News:Red Cross Shelters Hundreds as Severe Weather Hits Northeast 2
The KMedic Jet Wire Twister is designed to provide fast, smooth and even twisting of soft wire, saving time in the O.R. Now available for the first time in stainless steel. Suitable for the entire ra...
Lead filled and faced bone mallet used to exert force on osteotomes, chisels, and gouges....
Slightly curved Periosteal elevator....
Straight chisel for scoring, cutting, scraping, cleaning and sculpting bone....
Medicine Products: